



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Tarceva® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Non-small cell lung cancer (NSCLC)</p> <p><input type="checkbox"/> Pancreatic cancer</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Provider's Specialty:</p> <p>Is Tarceva prescribed by or in consultation with an oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For non-small cell lung cancer (NSCLC), answer the following:</p> <p>Does the patient have locally advanced or metastatic (stage III or IV) NSCLC? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have known active epidermal growth factor receptor (EGFR) exon 19 deletions, exon 21 (L858R) substitution, exon 18 (G719X, G719) or exon 20 (S7681) mutation as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For pancreatic cancer, answer the following:</p> <p>Does the patient have locally advanced, unresectable, or metastatic pancreatic cancer? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Will Tarceva be used in combination with Gemzar (gemcitabine)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Reauthorization:</p> <p>If this is a reauthorization request, answer the following question:</p> <p>Does the patient show evidence of progressive disease while on Tarceva therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity Limit Requests:</p> <p>What is the quantity requested per DAY? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-800-711-4555.
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Tarceva_Comm_2017Jun-W